| 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280] | Technology appraisal guidance | |
| Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059] | Technology appraisal guidance | TBC |
| Abatacept for preventing moderate to severe acute graft-versus-host disease after haematopoietic stem cell transplant in people 6 years and over [ID6185] | Technology appraisal guidance | TBC |
| Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230] | Technology appraisal guidance | TBC |
| Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer TSID 12065 | Technology appraisal guidance | TBC |
| Abicipar pegol for treating wet age-related macular degeneration ID1533 | Technology appraisal guidance | TBC |
| Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768] | Technology appraisal guidance | TBC |
| Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155] | Technology appraisal guidance | |
| Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer ID6339 | Technology appraisal guidance | |
| Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer [ID6368] | Technology appraisal guidance | |
| ALXN1840 for treating Wilson disease TS ID 9950 | Technology appraisal guidance | TBC |
| Alzheimer's disease (early) - gantenerumab [ID6142] | Technology appraisal guidance | TBC |
| Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110] | Technology appraisal guidance | |
| Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer ID6256 | Technology appraisal guidance | |
| Amyotrophic lateral sclerosis - SAR443820 [ID6386] | Technology appraisal guidance | TBC |
| Anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours [ID1001] | Technology appraisal guidance | |
| Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215] | Technology appraisal guidance | TBC |
| Asunercept for treating glioblastoma [1301] | Technology appraisal guidance | TBC |
| Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701 | Technology appraisal guidance | TBC |
| Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200] | Technology appraisal guidance | TBC |
| Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052] | Technology appraisal guidance | TBC |
| Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730] | Technology appraisal guidance | TBC |
| Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (MA review of TA823) [ID6324] | Technology appraisal guidance | |
| Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable [ID6218] | Technology appraisal guidance | TBC |
| Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148] | Technology appraisal guidance | TBC |
| Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203] | Technology appraisal guidance | TBC |
| Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213] | Technology appraisal guidance | TBC |
| Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152] | Technology appraisal guidance | TBC |
| Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000] | Technology appraisal guidance | TBC |
| Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707] | Technology appraisal guidance | TBC |
| Avapritinib for treating advanced systemic mastocytosis ID3770 | Technology appraisal guidance | |
| Avelumab for previously treated platinum-resistant ovarian cancer ID1497 | Technology appraisal guidance | TBC |
| Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261] | Technology appraisal guidance | TBC |
| Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294] | Technology appraisal guidance | |
| Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108] | Technology appraisal guidance | TBC |
| Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701] | Technology appraisal guidance | TBC |
| Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212 | Technology appraisal guidance | |
| Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211 | Technology appraisal guidance | |
| Belzutifan for previously treated advanced renal cell carcinoma [ID6154] | Technology appraisal guidance | TBC |
| Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093] | Technology appraisal guidance | TBC |
| Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis ID6266 | Technology appraisal guidance | |
| Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen ID6462 | Technology appraisal guidance | TBC |
| Bevacizumab gamma for treating wet age-related macular degeneration [ID6320] | Technology appraisal guidance | |
| Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145] | Technology appraisal guidance | |
| BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296] | Technology appraisal guidance | TBC |
| Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180] | Technology appraisal guidance | TBC |
| Bimekizumab for treating moderate to severe hidradenitis suppurativa [ID6134] | Technology appraisal guidance | TBC |
| Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease [ID6405] | Technology appraisal guidance | |
| Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768] | Technology appraisal guidance | TBC |
| Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334] | Technology appraisal guidance | |
| Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments [ID6325](review of TA677) | Technology appraisal guidance | |
| Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ] | Technology appraisal guidance | TBC |
| Cabotegravir for preventing HIV-1 in adults and young people [ID6255] | Technology appraisal guidance | |
| Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243] | Technology appraisal guidance | |
| Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330] | Technology appraisal guidance | TBC |
| Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653] | Technology appraisal guidance | TBC |
| Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370] | Technology appraisal guidance | |
| Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383] | Technology appraisal guidance | TBC |
| Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639] | Technology appraisal guidance | TBC |
| Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949] | Technology appraisal guidance | |
| Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012] | Technology appraisal guidance | TBC |
| Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259] | Technology appraisal guidance | TBC |
| Cladribine for treating relapsing multiple sclerosis [ID6263] | Technology appraisal guidance | |
| Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398] | Technology appraisal guidance | TBC |
| Colon cancer (adjuvant) - irinotecan [ID379] | Technology appraisal guidance | TBC |
| Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826] | Technology appraisal guidance | TBC |
| Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (MA review of TA529) [ID6289] | Technology appraisal guidance | |
| Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over [ID6140] | Technology appraisal guidance | TBC |
| Dapagliflozin for treating chronic kidney disease [ID6411] | Technology appraisal guidance | |
| Daprodustat for treating anaemia in people with chronic kidney disease [ID3987] | Technology appraisal guidance | TBC |
| Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843] | Technology appraisal guidance | TBC |
| Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297 | Technology appraisal guidance | TBC |
| Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297 | Technology appraisal guidance | |
| Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348] | Technology appraisal guidance | TBC |
| Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241] | Technology appraisal guidance | |
| DCVax-L for treating glioblastoma [ID836] | Technology appraisal guidance | TBC |
| Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419] | Technology appraisal guidance | TBC |
| Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897 | Technology appraisal guidance | TBC |
| Delgocitinib for treating moderate to severe chronic hand eczema ID6408 | Technology appraisal guidance | TBC |
| Dexmedetomidine for treating agitation associated with bipolar disorder in people 18 to 75 years [TS ID 10725] | Technology appraisal guidance | TBC |
| Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726 | Technology appraisal guidance | TBC |
| Diabetic retinopathy - ruboxistaurin [ID382] | Technology appraisal guidance | TBC |
| Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222] | Technology appraisal guidance | |
| Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency ID6415 | Technology appraisal guidance | TBC |
| Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314] | Technology appraisal guidance | TBC |
| Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055] | Technology appraisal guidance | TBC |
| Dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235 | Technology appraisal guidance | TBC |
| Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263] | Technology appraisal guidance | TBC |
| Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation ID5073 | Technology appraisal guidance | |
| Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer [ID6220] | Technology appraisal guidance | TBC |
| Durvalumab with concurrent chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906] | Technology appraisal guidance | TBC |
| Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317 | Technology appraisal guidance | |
| Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725] | Technology appraisal guidance | |
| Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076] | Technology appraisal guidance | TBC |
| Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170] | Technology appraisal guidance | TBC |
| Efgartigimod for treating generalised myasthenia gravis [ID4003] | Technology appraisal guidance | TBC |
| Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060] | Technology appraisal guidance | |
| Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225] | Technology appraisal guidance | TBC |
| Elafibranor for treating primary biliary cholangitis [ID6331] | Technology appraisal guidance | |
| Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments [ID4026] | Technology appraisal guidance | |
| Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240] | Technology appraisal guidance | TBC |
| Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177] | Technology appraisal guidance | |
| Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845] | Technology appraisal guidance | |
| Enfortumab vedotin with pembrolizumab for first-line treatment of unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy [ID6332] | Technology appraisal guidance | |
| Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6338] | Technology appraisal guidance | TBC |
| Eplontersen for treating hereditary transthyretin-related amyloidosis [ID6337] | Technology appraisal guidance | |
| ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623] | Technology appraisal guidance | TBC |
| Erdafitinib for previously treated FGFR-positive advanced solid tumours in people aged 6 and over [ID4058] | Technology appraisal guidance | TBC |
| Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333] | Technology appraisal guidance | |
| Evobrutinib for treating relapsing multiple sclerosis [ID6313] | Technology appraisal guidance | TBC |
| Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920 | Technology appraisal guidance | TBC |
| Exagamglogene autotemcel for treating sickle cell disease [ID4016] | Technology appraisal guidance | TBC |
| Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (Review of TA756) [ID5115] | Technology appraisal guidance | |
| Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651] | Technology appraisal guidance | TBC |
| Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071] | Technology appraisal guidance | |
| Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032] | Technology appraisal guidance | TBC |
| Filgotinib for treating moderately to severely active Crohn's disease [ID6236] | Technology appraisal guidance | TBC |
| Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133] | Technology appraisal guidance | TBC |
| Fruquintinib for previously treated metastatic colorectal cancer ID6274 | Technology appraisal guidance | |
| Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988] | Technology appraisal guidance | TBC |
| Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394] | Technology appraisal guidance | |
| Gilteritinib for maintenance treatment of FLT3-mutation-positive acute myeloid leukaemia after stem cell transplant [ID6243] | Technology appraisal guidance | TBC |
| Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323] | Technology appraisal guidance | TBC |
| Glaucoma - lerdelimumab (CAT-152) [ID383] | Technology appraisal guidance | TBC |
| Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma [ID6202] | Technology appraisal guidance | TBC |
| Guselkumab for previously treated moderately to severely active Crohn's disease ID6238 | Technology appraisal guidance | TBC |
| Guselkumab for treating moderately to severely active ulcerative colitis ID6237 | Technology appraisal guidance | TBC |
| Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627] | Technology appraisal guidance | TBC |
| Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343] | Technology appraisal guidance | |
| Ibrutinib for treating relapsed or refractory follicular lymphoma [1251] | Technology appraisal guidance | TBC |
| Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID1251] | Technology appraisal guidance | TBC |
| Ibrutinib for untreated mantle cell lymphoma [ID1221] | Technology appraisal guidance | TBC |
| Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547] | Technology appraisal guidance | |
| Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922] | Technology appraisal guidance | TBC |
| Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373] | Technology appraisal guidance | TBC |
| Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992] | Technology appraisal guidance | TBC |
| Insulin icodec for treating type 2 diabetes [ID6175] | Technology appraisal guidance | TBC |
| Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355] | Technology appraisal guidance | TBC |
| Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889] | Technology appraisal guidance | TBC |
| Iptacopan for treating complement 3 glomerulopathy ID6283 | Technology appraisal guidance | TBC |
| Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable ID3981 | Technology appraisal guidance | |
| Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067] | Technology appraisal guidance | TBC |
| Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706] | Technology appraisal guidance | TBC |
| KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 [ID1336] | Technology appraisal guidance | TBC |
| Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687] | Technology appraisal guidance | TBC |
| Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043] | Technology appraisal guidance | |
| Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410] | Technology appraisal guidance | TBC |
| Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966] | Technology appraisal guidance | TBC |
| Leriglitazone for treating andrenoleukodystrophy [ID3903] | Technology appraisal guidance | TBC |
| Letermovir for preventing cytomegalovirus infection after a kidney transplant [ID6166] | Technology appraisal guidance | TBC |
| Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390] | Technology appraisal guidance | TBC |
| Lifileucel for previously treated unresectable or metastatic melanoma ID3863 | Technology appraisal guidance | TBC |
| Linzagolix for treating symptoms of endometriosis [ID6357] | Technology appraisal guidance | |
| Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174] | Technology appraisal guidance | TBC |
| Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphomas after first-line chemotherapy when a stem cell transplant is suitable [ID3887] | Technology appraisal guidance | |
| LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844] | Technology appraisal guidance | TBC |
| Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434] | Technology appraisal guidance | |
| Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44] | Technology appraisal guidance | TBC |
| Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43] | Technology appraisal guidance | TBC |
| Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340 | Technology appraisal guidance | TBC |
| Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872] | Technology appraisal guidance | TBC |
| Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941] | Technology appraisal guidance | TBC |
| Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818] | Technology appraisal guidance | TBC |
| Maribavir for cytomegalovirus infection after haematopoietic stem cell transplant [ID5075] | Technology appraisal guidance | TBC |
| Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342] | Technology appraisal guidance | |
| Masitinib with riluzole for treating amyotrophic lateral sclerosis ID6257 | Technology appraisal guidance | TBC |
| Melanoma (metastatic) - talimogene laherparepvec [ID508] | Technology appraisal guidance | |
| Mirikizumab for treating moderately to severely active Crohn's disease [ID6244] | Technology appraisal guidance | TBC |
| Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527] | Technology appraisal guidance | TBC |
| Molnupiravir for treating COVID 19 [ID6340] | Technology appraisal guidance | |
| MTX110 for untreated diffuse intrinsic pontine glioma [ID2695] | Technology appraisal guidance | TBC |
| Multiple sclerosis (relapsing, remitting, highly active) - natalizumab and Tyruko (natalizumab biosimilar) (after disease modifying therapy) [ID6369] | Technology appraisal guidance | |
| Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID5096] | Technology appraisal guidance | TBC |
| Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over ID6221 | Technology appraisal guidance | |
| Nemolizumab for treating prurigo nodularis [ID6451] | Technology appraisal guidance | |
| Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858] | Technology appraisal guidance | |
| Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194] | Technology appraisal guidance | TBC |
| Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310] | Technology appraisal guidance | TBC |
| Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858] | Technology appraisal guidance | |
| Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362] | Technology appraisal guidance | TBC |
| Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053] | Technology appraisal guidance | TBC |
| Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102] | Technology appraisal guidance | TBC |
| Nivolumab with docetaxel for treating hormone-relapsed advanced prostate cancer after 1 or 2 hormonal therapies [ID4048] | Technology appraisal guidance | TBC |
| Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136] | Technology appraisal guidance | TBC |
| Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma ID1629 | Technology appraisal guidance | TBC |
| Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939] | Technology appraisal guidance | TBC |
| Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248] | Technology appraisal guidance | TBC |
| Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195] | Technology appraisal guidance | TBC |
| NY-ESO-1 T-cells for treating synovial sarcoma ID1286 | Technology appraisal guidance | TBC |
| Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [ID6347] | Technology appraisal guidance | |
| Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645] | Technology appraisal guidance | TBC |
| Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181] | Technology appraisal guidance | TBC |
| Olaparib for maintenance treatment of BRCA-negative platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer [ID6205] | Technology appraisal guidance | TBC |
| Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336] | Technology appraisal guidance | TBC |
| Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065] | Technology appraisal guidance | TBC |
| Omaveloxolone for treating Friedreich's ataxia in people 16 years and over ID6423 | Technology appraisal guidance | |
| Omburtamab for treating relapsed neuroblastoma [ID1664] | Technology appraisal guidance | TBC |
| Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111] | Technology appraisal guidance | TBC |
| OrganOx metra for liver transplant [ID5116] | Technology appraisal guidance | TBC |
| Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120] | Technology appraisal guidance | TBC |
| Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223] | Technology appraisal guidance | |
| Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328] | Technology appraisal guidance | TBC |
| Otilimab for treating moderate to severe rheumatoid arthritis [ID6171] | Technology appraisal guidance | TBC |
| Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089] | Technology appraisal guidance | TBC |
| Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144] | Technology appraisal guidance | TBC |
| Palopegteriparatide for treating chronic hypoparathyroidism [ID6380] | Technology appraisal guidance | |
| Parsaclisib for treating relapsed or refractory marginal zone lymphoma [ID3976] | Technology appraisal guidance | TBC |
| Pegcetacoplan for amyotrophic lateral sclerosis TS ID 10594 | Technology appraisal guidance | TBC |
| Pegcetacoplan for treating geographic atrophy [ID4041] | Technology appraisal guidance | TBC |
| Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer [ID6461] | Technology appraisal guidance | TBC |
| Pembrolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID5094] | Technology appraisal guidance | |
| Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy ID 6473 | Technology appraisal guidance | TBC |
| Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907] | Technology appraisal guidance | |
| Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138] | Technology appraisal guidance | TBC |
| Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696] | Technology appraisal guidance | TBC |
| Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207] | Technology appraisal guidance | TBC |
| Pembrolizumab with chemotherapy for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363] | Technology appraisal guidance | TBC |
| Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103] | Technology appraisal guidance | TBC |
| Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861] | Technology appraisal guidance | TBC |
| Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112] | Technology appraisal guidance | TBC |
| Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID5109] | Technology appraisal guidance | TBC |
| Pembrolizumab with lenvatinib for untreated advanced melanoma [ID3948] | Technology appraisal guidance | TBC |
| Pembrolizumab with lenvatinib for untreated PD-L1 positive recurrent or metastatic squamous cell head and neck cancer [ID5118] | Technology appraisal guidance | TBC |
| Pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell lung cancer [ID4006] | Technology appraisal guidance | TBC |
| Pembrolizumab with olaparib for maintenance treatment of non-squamous metastatic non-small-cell lung cancer after pembrolizumab with platinum-based chemotherapy [ID4028] | Technology appraisal guidance | TBC |
| Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814] | Technology appraisal guidance | TBC |
| Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously TKI-treated EGFR-positive metastatic non-squamous non-small-cell lung cancer [ID3873] | Technology appraisal guidance | TBC |
| Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma [ID4044] | Technology appraisal guidance | |
| Pembrolizumab with platinum chemotherapy, pemetrexed and lenvatinib for untreated advanced non-squamous non-small-cell lung cancer [ID3985] | Technology appraisal guidance | TBC |
| Pembrolizumab with platinum-based chemotherapy then pembrolizumab maintenance for treating primary advanced or recurrent endometrial cancer ID6381 | Technology appraisal guidance | |
| Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149] | Technology appraisal guidance | TBC |
| Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361] | Technology appraisal guidance | TBC |
| Pemigatinib for treating myeloid or lymphoid neoplasms with a FGFR1 rearrangement [ID6172] | Technology appraisal guidance | TBC |
| Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724] | Technology appraisal guidance | TBC |
| Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269] | Technology appraisal guidance | TBC |
| Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975] | Technology appraisal guidance | TBC |
| Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397] | Technology appraisal guidance | TBC |
| Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353 | Technology appraisal guidance | TBC |
| Port Delivery System with ranibizumab for treating wet age-related macular degeneration [ID3983] | Technology appraisal guidance | TBC |
| Pralsetinib for thyroid cancer [ID4018] | Technology appraisal guidance | TBC |
| Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056] | Technology appraisal guidance | |
| Relugolix–estradiol–norethisterone for treating symptoms of endometriosis [ID3982] | Technology appraisal guidance | TBC |
| Renal cell carcinoma Pathways Pilot [ID6186] | Technology appraisal guidance | TBC |
| Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277] | Technology appraisal guidance | TBC |
| Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer TSID 12007 | Technology appraisal guidance | TBC |
| Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307) | Technology appraisal guidance | TBC |
| Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153] | Technology appraisal guidance | |
| Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601] | Technology appraisal guidance | TBC |
| Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496] | Technology appraisal guidance | TBC |
| Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596] | Technology appraisal guidance | TBC |
| Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092] | Technology appraisal guidance | TBC |
| Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID5100] | Technology appraisal guidance | TBC |
| Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377] | Technology appraisal guidance | |
| Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427] | Technology appraisal guidance | TBC |
| Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998] | Technology appraisal guidance | TBC |
| Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375] | Technology appraisal guidance | TBC |
| Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033] | Technology appraisal guidance | TBC |
| Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150] | Technology appraisal guidance | TBC |
| Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over ID6284 | Technology appraisal guidance | TBC |
| Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738] | Technology appraisal guidance | TBC |
| Seladelpar for previously treated primary biliary cholangitis ID6429 | Technology appraisal guidance | TBC |
| Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a cancer drug in people 12 years and over (managed access review of TA742) [ID6288] | Technology appraisal guidance | |
| Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132] | Technology appraisal guidance | TBC |
| Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293] | Technology appraisal guidance | TBC |
| Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273] | Technology appraisal guidance | TBC |
| Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183] | Technology appraisal guidance | TBC |
| Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and living with overweight or obesity ID6441 | Technology appraisal guidance | TBC |
| Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer ID6346 | Technology appraisal guidance | TBC |
| Sipavibart for preventing COVID 19 [ID6282] | Technology appraisal guidance | TBC |
| Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440] | Technology appraisal guidance | |
| Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246] | Technology appraisal guidance | TBC |
| Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439] | Technology appraisal guidance | |
| Somapacitan for treating growth hormone deficiency in children [ID6178] | Technology appraisal guidance | TBC |
| Sotatercept for treating pulmonary arterial hypertension [ID6163] | Technology appraisal guidance | |
| Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632 | Technology appraisal guidance | TBC |
| Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287] | Technology appraisal guidance | |
| Sparsentan for treating primary IgA nephropathy [ID6308] | Technology appraisal guidance | |
| Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668] | Technology appraisal guidance | |
| Spesolimab for preventing generalised pustular psoriasis flares [ID6216] | Technology appraisal guidance | TBC |
| Spesolimab for treating generalised pustular psoriasis flares [ID3963] | Technology appraisal guidance | |
| Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001] | Technology appraisal guidance | TBC |
| Talacotuzumab for untreated acute myeloid leukaemia [ID1262] | Technology appraisal guidance | TBC |
| Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004] | Technology appraisal guidance | |
| Tarlatamab for previously treated advanced small-cell lung cancer [ID6364] | Technology appraisal guidance | |
| Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401 | Technology appraisal guidance | TBC |
| Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441] | Technology appraisal guidance | TBC |
| Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (Review of TA869) [ID6333] | Technology appraisal guidance | |
| Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253] | Technology appraisal guidance | TBC |
| Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259] | Technology appraisal guidance | |
| Teprotumumab for treating thyroid eye disease [ID6432] | Technology appraisal guidance | |
| Third molars (impacted) - prophylactic removal [ID898] | Technology appraisal guidance | TBC |
| Tirzepatide for managing overweight and obesity [ID6179] | Technology appraisal guidance | |
| Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy [ID4070] | Technology appraisal guidance | TBC |
| Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753] | Technology appraisal guidance | TBC |
| Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767] | Technology appraisal guidance | TBC |
| Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391] | Technology appraisal guidance | TBC |
| Tralokinumab for treating moderate to severe atopic dermatitis [ID3734] | Technology appraisal guidance | TBC |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309] | Technology appraisal guidance | |
| Treatments for non-small-cell lung cancer [ID6234] | Technology appraisal guidance | TBC |
| Triheptanoin for treating long-chain fatty acid oxidation disorders ID3891 | Technology appraisal guidance | TBC |
| Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165] | Technology appraisal guidance | TBC |
| Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227] | Technology appraisal guidance | TBC |
| Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell lung cancer [ID4061] | Technology appraisal guidance | TBC |
| Ublituximab for treating relapsing multiple sclerosis [ID6350] | Technology appraisal guidance | TBC |
| Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733] | Technology appraisal guidance | TBC |
| Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821] | Technology appraisal guidance | TBC |
| Vamorolone for treating Duchenne muscular dystrophy [ID4024] | Technology appraisal guidance | TBC |
| Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over ID6372 | Technology appraisal guidance | TBC |
| Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277] | Technology appraisal guidance | TBC |
| Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314] | Technology appraisal guidance | TBC |
| Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565 | Technology appraisal guidance | TBC |
| Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040] | Technology appraisal guidance | TBC |
| Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable [ID6291] | Technology appraisal guidance | TBC |
| Venglustat for treating gangliosidoses in people 2 years and over ID 6358 | Technology appraisal guidance | TBC |
| Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360] | Technology appraisal guidance | TBC |
| Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425] | Technology appraisal guidance | TBC |
| Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over ID6407 | Technology appraisal guidance | TBC |
| Vutrisiran for treating transthyretin-related amyloidosis with cardiomyopathy ID6470 | Technology appraisal guidance | TBC |
| Waldenstrom's macroglobulinaemia - ibrutinib [ID884] | Technology appraisal guidance | |
| Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199] | Technology appraisal guidance | TBC |
| Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392] | Technology appraisal guidance | |
| Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079] | Technology appraisal guidance | TBC |
| Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008] | Technology appraisal guidance | TBC |
| Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma [ID5123] | Technology appraisal guidance | TBC |
| Zuranolone for treating severe postnatal depression ID6431 | Technology appraisal guidance | TBC |